JP2017506233A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506233A5 JP2017506233A5 JP2016550629A JP2016550629A JP2017506233A5 JP 2017506233 A5 JP2017506233 A5 JP 2017506233A5 JP 2016550629 A JP2016550629 A JP 2016550629A JP 2016550629 A JP2016550629 A JP 2016550629A JP 2017506233 A5 JP2017506233 A5 JP 2017506233A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- creatine
- omega
- disorder
- depressive disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461937328P | 2014-02-07 | 2014-02-07 | |
| US61/937,328 | 2014-02-07 | ||
| PCT/US2015/014856 WO2015120299A1 (en) | 2014-02-07 | 2015-02-06 | Combination of creatine, an omega-3 fatty acid, and citicoline |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017506233A JP2017506233A (ja) | 2017-03-02 |
| JP2017506233A5 true JP2017506233A5 (cg-RX-API-DMAC7.html) | 2018-03-22 |
Family
ID=53778486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550629A Pending JP2017506233A (ja) | 2014-02-07 | 2015-02-06 | クレアチン、ω−３脂肪酸、及びシチコリンの組み合わせ |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10058552B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3102227A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017506233A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20160137528A (cg-RX-API-DMAC7.html) |
| CN (1) | CN106102765A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015120299A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10058552B2 (en) | 2014-02-07 | 2018-08-28 | University Of Utah Research Foundation | Combination of creatine, an omega-3 fatty acid, and citicoline |
| AU2018204841B2 (en) * | 2017-07-05 | 2023-08-10 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for treating post-traumatic stress disorder in patients via renal neuromodulation |
| KR102269106B1 (ko) | 2017-11-20 | 2021-06-24 | 주식회사 엘지화학 | 배터리 파워 한계 값 제어 방법 |
| EP3563830A1 (en) | 2018-05-03 | 2019-11-06 | Commissariat à l'énergie atomique et aux énergies alternatives | Micro-emulsion containing creatine fatty ester, method for preparing said micro-emulsion and uses thereof |
| KR102141737B1 (ko) * | 2018-10-23 | 2020-08-05 | 이화여자대학교 산학협력단 | 크레아틴 및 타우린의 혼합물을 함유하는 우울장애 및 불안장애의 치료용 약학적 조성물 |
| EP3732995A1 (en) * | 2019-04-30 | 2020-11-04 | Commissariat à l'énergie atomique et aux énergies alternatives | Composition containing creatine fatty ester for use in medicine |
| CN119173259A (zh) * | 2022-05-12 | 2024-12-20 | 澳泽化学特罗斯特贝格有限公司 | 用于治疗呼吸困难的包含肌酸的组合物 |
| IT202300026181A1 (it) * | 2023-12-06 | 2025-06-06 | Hope S R L | Potenziata composizione per prevenire e trattare patologie neurodegenerative e disturbi cognitivi quali parkinson e halzheimer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU731692C (en) * | 1996-10-11 | 2001-10-11 | Scarista Limited | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid |
| US20070004670A1 (en) | 1998-07-31 | 2007-01-04 | Richard Wurtman | Compositions containing citicoline, and methods of use thereof |
| DE19929995B4 (de) | 1999-06-30 | 2004-06-03 | Skw Trostberg Ag | Verwendung von Kreatin und/oder Kreatin-Derivaten zur Behandlung von Befindlichkeitsstörungen bei Frauen |
| ES2425114T3 (es) * | 2000-03-16 | 2013-10-11 | The Mclean Hospital Corporation | CDP-colina y uridina para el tratamiento del abuso del acohol |
| US6964969B2 (en) * | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
| US20050287204A1 (en) * | 2002-06-19 | 2005-12-29 | Hageman Robert J J | Nutritional or pharmaceutical compositions for increasing the creatine response of organisms |
| EP1727554A4 (en) | 2003-10-08 | 2009-09-30 | Mclean Hospital Corp | METHODS OF TREATING PSYCHIATRIC DISORDERS, ALCOHOL AND DRUG ABUSE DISORDERS, AND OTHER DISORDERS USING COMBINATIONS CONTAINING OMEGA 3 FATTY ACIDS |
| US20050143350A1 (en) | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
| US7776915B2 (en) | 2005-03-24 | 2010-08-17 | Tracie Martyn International, Llc | Topical formulations and methods of use |
| DE102006016227A1 (de) * | 2006-04-06 | 2007-10-11 | Degussa Gmbh | Verfahren zur Herstellung von Kreatin, Kreatin-Monohydrat oder Guanidinoessigsäure |
| US20110274680A1 (en) * | 2009-10-02 | 2011-11-10 | Mazed Mohammad A | Chemical composition and its delivery for lowering the risks of alzheimer's, cardiov ascular and type-2 diabetes diseases |
| EP2568826A4 (en) | 2010-05-13 | 2014-03-26 | Nitromega Corp | NITRATED FATTY ACIDS, NEUROPROTECTION AND / OR INHIBITION OF COGNITIVE DECLINE |
| WO2011143534A1 (en) | 2010-05-13 | 2011-11-17 | The Mclean Hospital Corporation | Methods for the treatment of psychiatric disorders |
| US20130324609A1 (en) * | 2010-10-08 | 2013-12-05 | University Of Utah Research Foundation | Depression disorder therapeutics with creatine analogs |
| US10058552B2 (en) | 2014-02-07 | 2018-08-28 | University Of Utah Research Foundation | Combination of creatine, an omega-3 fatty acid, and citicoline |
-
2015
- 2015-02-06 US US15/117,143 patent/US10058552B2/en not_active Expired - Fee Related
- 2015-02-06 WO PCT/US2015/014856 patent/WO2015120299A1/en not_active Ceased
- 2015-02-06 JP JP2016550629A patent/JP2017506233A/ja active Pending
- 2015-02-06 EP EP15746527.9A patent/EP3102227A4/en not_active Withdrawn
- 2015-02-06 KR KR1020167024567A patent/KR20160137528A/ko not_active Ceased
- 2015-02-06 CN CN201580013800.XA patent/CN106102765A/zh active Pending
-
2018
- 2018-03-08 US US15/916,140 patent/US10265317B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506233A5 (cg-RX-API-DMAC7.html) | ||
| PH12021550328A1 (en) | Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject | |
| Kaur et al. | Short-term docosapentaenoic acid (22: 5n-3) supplementation increases tissue docosapentaenoic acid, DHA and EPA concentrations in rats | |
| NZ600740A (en) | Compositions containing pufa and/or uridine and methods of use thereof | |
| JP2012516852A5 (cg-RX-API-DMAC7.html) | ||
| US6340705B1 (en) | Use of α-linolenic acid metabolites for treatment or prevention of cancer | |
| JP2019048843A5 (cg-RX-API-DMAC7.html) | ||
| TN2021000013A1 (en) | Methods of reducing the risk of cardiovascular events in a subject | |
| JP2015147773A5 (cg-RX-API-DMAC7.html) | ||
| IN2014DN08449A (cg-RX-API-DMAC7.html) | ||
| NZ712068A (en) | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity | |
| JP2020500193A5 (cg-RX-API-DMAC7.html) | ||
| JP2015143248A5 (cg-RX-API-DMAC7.html) | ||
| JP2013521310A5 (cg-RX-API-DMAC7.html) | ||
| JP2016516040A5 (cg-RX-API-DMAC7.html) | ||
| NZ600167A (en) | Concentrated therapeutic phospholipid compositions | |
| EP4338805A3 (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| HK1204272A1 (en) | Methods of treating pediatric metabolic syndrome | |
| JP2020500875A5 (cg-RX-API-DMAC7.html) | ||
| JP2016511753A5 (cg-RX-API-DMAC7.html) | ||
| JP2016053065A5 (cg-RX-API-DMAC7.html) | ||
| WO2012049227A3 (en) | Novel omega-3 and omega-6 fatty acid compositions and uses thereof | |
| WO2017077528A3 (en) | Methods and pharmaceutical compositions for treatment of lung inflammation | |
| JP2006219454A5 (cg-RX-API-DMAC7.html) | ||
| JP2018515463A5 (cg-RX-API-DMAC7.html) |